使用拉索逻辑回归来确定SARS1作为侵袭性叶状癌的预后生物标志物
Tyrel Porter1, Isaí Soto-Colón1, Emir Rinaldi-Pérez1
1School of Medicine, Universidad Central del Caribe, Bayamón, Puerto Rico.
microPublication biology
|September 4, 2025
概括
氨基酸tRNA合成酶 (ARS) 在癌症中很重要. 这项研究发现,高SARS1基因表达与侵袭性叶状癌 (ILC) 患者的存活率较低有关,并将其确定为潜在的预后生物标志物.
科学领域:
- 分子瘤学
- 癌症基因组学
- 生物标志物的发现
背景情况:
- 氨基酸tRNA合成酶 (ARS) 越来越多地被认为对癌症的发展和进展起作用.
- 之前的研究将TARS1,一种ARS与乳腺癌的预后不佳和免疫抑制联系在一起.
- 其他ARS基因在侵袭性叶状癌 (ILC) 的预后意义在很大程度上尚未探索.
研究的目的:
- 在侵袭性叶状癌 (ILC) 中确定41个ARS基因中的预后生物标志物.
- 在ILC中研究ARS基因表达与患者生存结果之间的关联.
- 评估ARS基因作为乳腺癌治疗点或预后指标的潜力.
主要方法:
- 使用癌症基因组图谱 (TCGA) 对41个ARS基因的RNA测序数据.
- 应用了拉索逻辑回归来确定与患者生命状态相关的显著ARS基因.
- 在5年和10年间进行生存分析以评估选定的ARS基因的预后值.
主要成果:
- 生存分析显示,SARS1表达的升高与患者5年和10年生存时间的减少显著相关.
- 在5年后,CARS2表达与生存率的降低有显著的关联,但在10年后却没有.
- 该研究确定SARS1是ILC预后生物标志物的有希望的候选者.
结论:
- 在侵袭性叶状癌 (ILC) 中,SARS1基因表达是显著的负预后因素.
- 对于ILC患者来说,CARS2也可能具有短期的预后意义.
- 这些发现强调了ARS基因在乳腺癌预后中的更广泛重要性,并需要进一步研究.
更多相关视频
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.1K
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.7K
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
01:21Cancer Survival Analysis
445
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
445